Secondary prevention of cervical cancer: ASCO resource-stratified clinical practice guideline

Journal of Global Oncology

Volumn 3, Issue 5, 2017, Pages 635-657

  Jeronimo, Jose ^a   Castle, Philip E ^b   Temin, Sarah ^c   Denny, Lynette ^d   Gupta, Vandana ^e   Kim, Jane J ^g   Luciani, Silvana ^h   Murokora, Daniel ⁱ   Ngoma, Twalib ^j   Qiao, Youlin ^k   Quinn, Michael ^l   Sankaranarayanan, Rengaswamy ^m   Sasieni, Peter ⁿ   Schmeler, Kathleen M ^o   Shastri, Surendra S ^f  

^a PATH   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e V Care ^*

^f TATA MEMORIAL HOSPITAL   (India)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^h PAN AMERICAN HEALTH ORGANIZATION   (United States)

ⁱ Uganda Women's Health Initiative   (Uganda)

^j INTERNATIONAL NETWORK FOR CANCER TREATMENT AND RESEARCH   (Belgium)

^k PEKING UNION MEDICAL COLLEGE   (China)

^l UNIVERSITY OF MELBOURNE   (Australia)

^m INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

ⁿ QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^o UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85096874648     PISSN: None     EISSN: 23789506     Source Type: Journal    
DOI: 10.1200/JGO.2016.006577     Document Type: Article

References (95)

1. International Agency for Research on Cancer: GLOBOCAN 2012 Cervical Cancer: Estimated incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/old/FactSheets/cancers/cervix-new.asp
2. Chuang LT, Temin S, Camacho R, et al: Management and care of women with invasive cervical cancer: American Society of Clinical Oncology resource-stratified clinical practice guideline. J Global Oncol 2:311-340, 2016
3. Sankaranarayanan R, Budukh AM, Rajkumar R: Effective screening programmes for cervical cancer in low- and middle-income developing countries. Bull World Health Organ 79:954-962, 2001
4. World Health Organization: Comprehensive Cervical Cancer Control: A Guide to Essential Practice (ed 2). Geneva, Switzerland, World Health Organization, 2014
5. von Karsa L, Arbyn M, De Vuyst H, et al: European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res 1:22-31, 2015
6. Huh WK, Ault KA, Chelmow D, et al: Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance. Obstet Gynecol 125:330-337, 2015
7. Adesina A, Chumba D, Nelson AM, et al: Improvement of pathology in sub-Saharan Africa. Lancet Oncol 14:e152-e157, 2013
8. Sayed S, Lukande R, Fleming KA: Providing pathology support in low-income countries. J Global Oncol 1:3-6, 2015
9. Olmsted SS, Moore M, Meili RC, et al: Strengthening laboratory systems in resource-limited settings. Am J Clin Pathol 134:374-380, 2010
10. Sankaranarayanan R, Anorlu R, Sangwa-Lugoma G, et al: Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa. Vaccine 31:F47-F52, 2013 (suppl 5)
11. Garland SM, Hernandez-Avila M, Wheeler CM, et al: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356:1928-1943, 2007
12. Hildesheim A, Herrero R, Wacholder S, et al: Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: A randomized trial. JAMA 298:743-753, 2007
13. National Cancer Institute: Cervical Cancer Screening–Health Professional Version (PDQ®). Bethesda, MD, National Cancer Institute, 2016
14. Darragh TM, Colgan TJ, Thomas Cox J, et al: The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: Background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol 32:76-115, 2013
15. Moyer VA, US Preventative Services Task Force: Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 156:880-891, W312, 2012
16. Anderson BO, Shyyan R, Eniu A, et al: Breast cancer in limited-resource countries: An overview of the Breast Health Global Initiative 2005 guidelines. Breast J 12:S3-S15, 2006 (suppl 1)
17. Horton S, Gauvreau CL: Cancer in low- and middle-income countries: An economic overview, in Gelband H, Jha P, Sankaranarayanan R, et al (eds): Cancer Disease Control Priorities (ed 3). Washington, DC, International Bank for Reconstruction and Development/World Bank, 2015
18. ADAPTE Collaboration: The ADAPTE Process: Guideline Adaptation: A Resource Toolkit (version 2.0). http://www.g-in.net/document-store/working-groups-documents/adaptation/adapte-resource-toolkit-guideline-adaptation-2-0.pdf
19. Shiffman RN, Michel G, Rosenfeld RM, et al: Building better guidelines with BRIDGE-Wiz: Development and evaluation of a software assistant to promote clarity, transparency, and implementability. J Am Med Inform Assoc 19: 94-101, 2012
20. Shi JF, Canfell K, Lew JB, et al: Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: An epidemiologic and cost-effectiveness modelling study. BMC Cancer 11: 239, 2011
21. Beal CM, Salmerón J, Flores YN, et al: Cost analysis of different cervical cancer screening strategies in Mexico. Salud Publica Mex 56:429-501, 2014
22. Vanni T, Legood R, Franco EL, et al: Economic evaluation of strategies for managing women with equivocal cytological results in Brazil. Int J Cancer 129:671-679, 2011
23. Campos NG, Tsu V, Jeronimo J, et al: When and how often to screen for cervical cancer in three low- and middle-income countries: A cost-effectiveness analysis. Papillomavirus Res 1:38-58, 2015
24. Saslow D, Solomon D, Lawson HW, et al: American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 62:147-172, 2012
25. Saslow D, Solomon D, Lawson HW, et al: American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis 16:175-204, 2012
26. Massad LS, Einstein MH, Huh WK, et al: 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 121:829-846, 2013
27. Murphy J, Kennedy EB, Dunn S, et al: Cervical screening: A guideline for clinical practice in Ontario. J Obstet Gynaecol Can 34:453-458, 2012
28. World Health Organization: WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention: WHO Guidelines Approved by the Guidelines Review Committee. Geneva, Switzerland, World Health Organization, 2013
29. World Health Organization: WHO Guidelines for Treatment of Cervical Intraepithelial Neoplasia 2-3 and Adenocarcinoma in Situ: Cryotherapy, Large Loop Excision of the Transformation Zone, and Cold Knife Conization. WHO Guidelines Approved by the Guidelines Review Committee. Geneva, Switzerland, World Health Organization, 2014
30. US Preventive Services Task Force: Final research plan for cervical cancer: Screening. http://www.uspreventiveservicestaskforce.org/Page/Document/final-research-plan/cervical-cancer-screening2
31. Brouwers MC, Kho ME, Browman GP, et al: AGREE II: Advancing guideline development, reporting and evaluation in health care. CMAJ 182:E839-E842, 2010
32. Jhpiego Corporation: Loop Electrosurgical Excision Procedure (LEEP) Services: A Reference Manual for Providers. Baltimore, MD, Jhpiego Corporation, 2015
33. Wright TC Jr, Stoler MH, Sharma A, et al: Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV1 cytology-negative results. Am J Clin Pathol 136:578-586, 2011
34. Dillner J, Rebolj M, Birembaut P, et al: Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: Joint European cohort study. BMJ 337:a1754, 2008
35. Ronco G, Dillner J, Elfström KM, et al: Efficacy of HPV-based screening for prevention of invasive cervical cancer: Follow-up of four European randomised controlled trials. Lancet 383:524-532, 2014
36. Rijkaart DC, Berkhof J, van Kemenade FJ, et al: HPV DNA testing in population-based cervical screening (VUSA-Screen study): Results and implications. Br J Cancer 106:975-981, 2012
37. C Kitchener H, Canfell K, Gilham C, et al: The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: Extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. Health Technol Assess 18:1-196, 2014
38. Arbyn M, Ronco G, Anttila A, et al: Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30:F88-F99, 2012 (suppl 5)
39. Harris LN, Ismaila N, McShane LM, et al: Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 34:1134-1150, 2016
40. Meijer CJ, Berkhof J, Castle PE, et al: Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 124:516-520, 2009
41. Stoler MH, Castle PE, Solomon D, et al: The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol 127:335-337, 2007
42. Martin-Hirsch PP, Paraskevaidis E, Bryant A, et al: Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev 12:CD001318, 2013
43. van der Heijden E, Lopes AD, Bryant A, et al: Follow-up strategies after treatment (large loop excision of the transformation zone (LLETZ)) for cervical intraepithelial neoplasia (CIN): Impact of human papillomavirus (HPV) test. Cochrane Database Syst Rev 1:CD010757, 2015
44. Castañón A, Landy R, Cuzick J, et al: Cervical screening at age 50-64 years and the risk of cervical cancer at age 65 years and older: Population-based case control study. PLoS Med 11:e1001585, 2014
45. The World Bank Group: GNI per capita, Atlas method (current US$). http://data.worldbank.org/indicator/NY.GNP.PCAP.CD?page51
46. Arbyn M, Anttila A, Jordan J, et al: European Guidelines for Quality Assurance in Cervical Cancer Screening: Second edition—Summary document. Ann Oncol 21:448-458, 2010
47. Cuzick J, Powles T, Veronesi U, et al: Overview of the main outcomes in breast-cancer prevention trials. Lancet 361: 296-300, 2003
48. Kotaniemi-Talonen L, Nieminen P, Anttila A, et al: Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer 93:862-867, 2005
49. Public Health England: NHS Cervical screening program: Colposcopy and programmer management, NHSCSP Publication number 20. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/508133/NHSCSP_20_3rd_ed.pdf
50. Bentley J, Society of Canadian Colposcopists: Colposcopic management of abnormal cervical cytology and histology. J Obstet Gynaecol Can 34:1188-1206, 2012
51. International Federation for Cervical Pathology and Colposcopy: International Federation for Cervical Pathology and Colposcopy Nomenclature. http://www.ifcpc.org/images/docs/nomenclature7-11.pdf
52. World Health Organization: WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention. WHO Guidelines Approved by the Guidelines Review Committee. Geneva, Switzerland, World Health Organization, 2013
53. The World Bank Group: Country and lending groups. http://data.worldbank.org/about/country-and-lending-groups
54. Shastri SS, Mittra I, Mishra GA, et al: Effect of VIA screening by primary health workers: Randomized controlled study in Mumbai, India. J Natl Cancer Inst 106:dju009, 2014
55. Sankaranarayanan R, Nene BM, Shastri SS, et al: HPV screening for cervical cancer in rural India. N Engl J Med 360: 1385-1394, 2009
56. Deodhar K, Sankaranarayanan R, Jayant K, et al: Accuracy of concurrent visual and cytology screening in detecting cervical cancer precursors in rural India. Int J Cancer 131:E954-E962, 2012
57. Nessa A, Hussain MA, Rahman JN, et al: Screening for cervical neoplasia in Bangladesh using visual inspection with acetic acid. Int J Gynaecol Obstet 111:115-118, 2010
58. Forhan SE, Godfrey CC, Watts DH, et al: A systematic review of the effects of visual inspection with acetic acid, cryotherapy, and loop electrosurgical excision procedures for cervical dysplasia in HIV-infected women in low- and middle-income countries. J Acquir Immune Defic Syndr 68:S350-S356, 2015 (suppl 3)
59. Vanni T, Luz PM, Grinsztejn B, et al: Cervical cancer screening among HIV-infected women: An economic evaluation in a middle-income country. Int J Cancer 131:E96-E104, 2012
60. Arbyn M, Verdoodt F, Snijders PJ, et al: Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: A meta-analysis. Lancet Oncol 15:172-183, 2014
61. Racey CS, Withrow DR, Gesink D: Self-collected HPV testing improves participation in cervical cancer screening: A systematic review and meta-analysis. Can J Public Health 104:e159-e166, 2013
62. Stewart DE, Gagliardi A, Johnston M, et al: Self-collected samples for testing of oncogenic human papillomavirus: A systematic review. J Obstet Gynaecol Can 29:817-828, 2007
63. Stoler MH, Wright TC Jr, Cuzick J, et al: APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results. Am J Obstet Gynecol 208:144.e1-8, 2013
64. Khan MJ, Castle PE, Lorincz AT, et al: The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97:1072-1079, 2005
65. de Sanjose S, Wheeler CM, Quint WG, et al: Age-specific occurrence of HPV16- and HPV18-related cervical cancer. Cancer Epidemiol Biomarkers Prev 22:1313-1318, 2013
66. Sasieni P, Castanon A, Cuzick J: Effectiveness of cervical screening with age: Population based case-control study of prospectively recorded data. BMJ 339:b2968, 2009
67. Katki HA, Schiffman M, Castle PE, et al: Benchmarking CIN 31 risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis 17:S28-S35, 2013 (suppl 1)
68. Castle PE, Rodríguez AC, Burk RD, et al: Short term persistence of human papillomavirus and risk of cervical precancer and cancer: Population based cohort study. BMJ 339:b2569, 2009
69. Kjær SK, Frederiksen K, Munk C, et al: Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: Role of persistence. J Natl Cancer Inst 102:1478-1488, 2010
70. Ikenberg H, Bergeron C, Schmidt D, et al: Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: Results of the PALMS study. J Natl Cancer Inst 105:1550-1557, 2013
71. Qiao YL, Jeronimo J, Zhao FH, et al: Lower cost strategies for triage of human papillomavirus DNA-positive women. Int J Cancer 134:2891-2901, 2014
72. Mirabello L, Sun C, Ghosh A, et al: Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population. J Natl Cancer Inst 104:556-565, 2012
73. Wentzensen N, Sun C, Ghosh A, et al: Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst 104:1738-1749, 2012
74. Kovacic MB, Castle PE, Herrero R, et al: Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res 66:10112-10119, 2006
75. Wentzensen N, Nason M, Schiffman M, et al: No evidence for synergy between human papillomavirus genotypes for the risk of high-grade squamous intraepithelial lesions in a large population-based study. J Infect Dis 209:855-864, 2014
76. Joste NE, Ronnett BM, Hunt WC, et al: Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer. Cancer Epidemiol Biomarkers Prev 24:230-240, 2015
77. Kinde I, Bettegowda C, Wang Y, et al: Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 5:167ra4, 2013
78. Carozzi F, Confortini M, Dalla Palma P, et al: Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: A nested substudy of the NTCC randomised controlled trial. Lancet Oncol 9:937-945, 2008
79. Carozzi F, Gillio-Tos A, Confortini M, et al: Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: A prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 14:168-176, 2013
80. Valdez M, Jeronimo J, Bansil P, et al: Effectiveness of novel, lower cost molecular human papillomavirus-based tests for cervical cancer screening in rural china. Int J Cancer 138:1453-1461, 2016
81. Zhao FH, Jeronimo J, Qiao YL, et al: An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China. Cancer Prev Res (Phila) 6:938-948, 2013
82. Brentnall AR, Vasiljević N, Scibior-Bentkowska D, et al: A DNA methylation classifier of cervical precancer based on human papillomavirus and human genes. Int J Cancer 135:1425-1432, 2014
83. Mirabello L, Schiffman M, Ghosh A, et al: Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia. Int J Cancer 132:1412-1422, 2013
84. Vasiljević N, Scibior-Bentkowska D, Brentnall AR, et al: Credentialing of DNA methylation assays for human genes as diagnostic biomarkers of cervical intraepithelial neoplasia in high-risk HPV positive women. Gynecol Oncol 132:709-714, 2014
85. Wentzensen N, Sherman ME, Schiffman M, et al: Utility of methylation markers in cervical cancer early detection: Appraisal of the state-of-the-science. Gynecol Oncol 112:293-299, 2009
86. Hesselink AT, Heideman DA, Steenbergen RD, et al: Methylation marker analysis of self-sampled cervico-vaginal lavage specimens to triage high-risk HPV-positive women for colposcopy. Int J Cancer 135:880-886, 2014
87. Verhoef VM, Bosgraaf RP, van Kemenade FJ, et al: Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): A randomised controlled non-inferiority trial. Lancet Oncol 15:315-322, 2014
88. Andersson S, Wallin KL, Hellström AC, et al: Frequent gain of the human telomerase gene TERC at 3q26 in cervical adenocarcinomas. Br J Cancer 95:331-338, 2006
89. Heselmeyer K, Schröck E, du Manoir S, et al: Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc Natl Acad Sci USA 93:479-484, 1996
90. Hopman AH, Theelen W, Hommelberg PP, et al: Genomic integration of oncogenic HPV and gain of the human telomerase gene TERC at 3q26 are strongly associated events in the progression of uterine cervical dysplasia to invasive cancer. J Pathol 210:412-419, 2006
91. Rao PH, Arias-Pulido H, Lu XY, et al: Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma. BMC Cancer 4:5, 2004
92. Thomas LK, Bermejo JL, Vinokurova S, et al: Chromosomal gains and losses in human papillomavirus-associated neoplasia of the lower genital tract: A systematic review and meta-analysis. Eur J Cancer 50:85-98, 2014
93. Andersson S, Sowjanya P, Wangsa D, et al: Detection of genomic amplification of the human telomerase gene TERC, a potential marker for triage of women with HPV-positive, abnormal Pap smears. Am J Pathol 175:1831-1847, 2009
94. Ojesina AI, Lichtenstein L, Freeman SS, et al: Landscape of genomic alterations in cervical carcinomas. Nature 506: 371-375, 2014
95. Vinokurova S, Wentzensen N, Kraus I, et al: Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res 68:307-313, 2008